APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Bevacizumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Bevacizumab Injection Market Outlook and Growth Opportunities 2026

Report ID 17397018042 January 2026191 pages

Choose your research edition.

Industry ResearchBevacizumab Injection Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Bevacizumab Injection Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Bevacizumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bevacizumab Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Bevacizumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Bevacizumab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Bevacizumab Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Bevacizumab Injection market include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bevacizumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bevacizumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bevacizumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bevacizumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Bevacizumab Injection Segment by Company

Biocon

Cadila Pharmaceuticals

Centus

Dr Reddy's

Genentech

Hetero Group

Samsung Bioepis

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Bevacizumab Injection Segment by Type

100mg

400mg

Bevacizumab Injection Segment by Application

Age-related macular degeneration (AMD)

Ovarian Cancer

Others

Bevacizumab Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Bevacizumab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Bevacizumab Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Bevacizumab Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Bevacizumab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bevacizumab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bevacizumab Injection industry.

Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Bevacizumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Bevacizumab Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Bevacizumab Injection Industry Trends Table 2. Bevacizumab Injection Industry Drivers Table 3. Bevacizumab Injection Industry Opportunities and Challenges Table 4. Bevacizumab Injection Industry Restraints Table 5. Global Bevacizumab Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Bevacizumab Injection Revenue Share by Company (2021-2026) Table 7. Global Bevacizumab Injection Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global Bevacizumab Injection Sales Volume Share by Company (2021-2026) Table 9. Global Bevacizumab Injection Average Price (US$/Dose) of Company (2021-2026) Table 10. Global Bevacizumab Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Bevacizumab Injection Key Company Manufacturing Base & Headquarters Table 12. Global Bevacizumab Injection Company, Product Type & Application Table 13. Global Bevacizumab Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Bevacizumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg Table 18. Significant Companies of 400mg Table 19. Global Bevacizumab Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 20. Global Bevacizumab Injection Sales Volume by Type (2021-2026) & (K Doses) Table 21. Global Bevacizumab Injection Sales Volume by Type (2027-2032) & (K Doses) Table 22. Global Bevacizumab Injection Sales Volume Share by Type (2021-2026) Table 23. Global Bevacizumab Injection Sales Volume Share by Type (2027-2032) Table 24. Global Bevacizumab Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Bevacizumab Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Bevacizumab Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Bevacizumab Injection Sales Value Share by Type (2021-2026) Table 28. Global Bevacizumab Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Age-related macular degeneration (AMD) Table 30. Significant Companies of Ovarian Cancer Table 31. Significant Companies of Others Table 32. Global Bevacizumab Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 33. Global Bevacizumab Injection Sales Volume by Application (2021-2026) & (K Doses) Table 34. Global Bevacizumab Injection Sales Volume by Application (2027-2032) & (K Doses) Table 35. Global Bevacizumab Injection Sales Volume Share by Application (2021-2026) Table 36. Global Bevacizumab Injection Sales Volume Share by Application (2027-2032) Table 37. Global Bevacizumab Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Bevacizumab Injection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Bevacizumab Injection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Bevacizumab Injection Sales Value Share by Application (2021-2026) Table 41. Global Bevacizumab Injection Sales Value Share by Application (2027-2032) Table 42. Global Bevacizumab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 43. Global Bevacizumab Injection Sales by Region (2021-2026) & (K Doses) Table 44. Global Bevacizumab Injection Sales Market Share by Region (2021-2026) Table 45. Global Bevacizumab Injection Sales by Region (2027-2032) & (K Doses) Table 46. Global Bevacizumab Injection Sales Market Share by Region (2027-2032) Table 47. Global Bevacizumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Bevacizumab Injection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Bevacizumab Injection Sales Value Share by Region (2021-2026) Table 50. Global Bevacizumab Injection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Bevacizumab Injection Sales Value Share by Region (2027-2032) Table 52. Global Bevacizumab Injection Market Average Price (US$/Dose) by Region (2021-2026) Table 53. Global Bevacizumab Injection Market Average Price (US$/Dose) by Region (2027-2032) Table 54. Global Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 55. Global Bevacizumab Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 57. Global Bevacizumab Injection Sales Market Share by Country (2021-2026) Table 58. Global Bevacizumab Injection Sales by Country (2027-2032) & (K Doses) Table 59. Global Bevacizumab Injection Sales Market Share by Country (2027-2032) Table 60. Global Bevacizumab Injection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Bevacizumab Injection Sales Value Market Share by Country (2021-2026) Table 62. Global Bevacizumab Injection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Bevacizumab Injection Sales Value Market Share by Country (2027-2032) Table 64. Biocon Company Information Table 65. Biocon Business Overview Table 66. Biocon Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 67. Biocon Bevacizumab Injection Product Portfolio Table 68. Biocon Recent Development Table 69. Cadila Pharmaceuticals Company Information Table 70. Cadila Pharmaceuticals Business Overview Table 71. Cadila Pharmaceuticals Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 72. Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio Table 73. Cadila Pharmaceuticals Recent Development Table 74. Centus Company Information Table 75. Centus Business Overview Table 76. Centus Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 77. Centus Bevacizumab Injection Product Portfolio Table 78. Centus Recent Development Table 79. Dr Reddy's Company Information Table 80. Dr Reddy's Business Overview Table 81. Dr Reddy's Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 82. Dr Reddy's Bevacizumab Injection Product Portfolio Table 83. Dr Reddy's Recent Development Table 84. Genentech Company Information Table 85. Genentech Business Overview Table 86. Genentech Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 87. Genentech Bevacizumab Injection Product Portfolio Table 88. Genentech Recent Development Table 89. Hetero Group Company Information Table 90. Hetero Group Business Overview Table 91. Hetero Group Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 92. Hetero Group Bevacizumab Injection Product Portfolio Table 93. Hetero Group Recent Development Table 94. Samsung Bioepis Company Information Table 95. Samsung Bioepis Business Overview Table 96. Samsung Bioepis Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 97. Samsung Bioepis Bevacizumab Injection Product Portfolio Table 98. Samsung Bioepis Recent Development Table 99. Amgen Company Information Table 100. Amgen Business Overview Table 101. Amgen Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 102. Amgen Bevacizumab Injection Product Portfolio Table 103. Amgen Recent Development Table 104. Bayer Company Information Table 105. Bayer Business Overview Table 106. Bayer Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 107. Bayer Bevacizumab Injection Product Portfolio Table 108. Bayer Recent Development Table 109. Pfizer Company Information Table 110. Pfizer Business Overview Table 111. Pfizer Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 112. Pfizer Bevacizumab Injection Product Portfolio Table 113. Pfizer Recent Development Table 114. Eli Lilly Company Information Table 115. Eli Lilly Business Overview Table 116. Eli Lilly Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 117. Eli Lilly Bevacizumab Injection Product Portfolio Table 118. Eli Lilly Recent Development Table 119. Roche Company Information Table 120. Roche Business Overview Table 121. Roche Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 122. Roche Bevacizumab Injection Product Portfolio Table 123. Roche Recent Development Table 124. Mylan Company Information Table 125. Mylan Business Overview Table 126. Mylan Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 127. Mylan Bevacizumab Injection Product Portfolio Table 128. Mylan Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Bevacizumab Injection Distributors List Table 132. Bevacizumab Injection Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Bevacizumab Injection Product Image Figure 2. Global Bevacizumab Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bevacizumab Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Bevacizumab Injection Sales (2021-2032) & (K Doses) Figure 5. Global Bevacizumab Injection Sales Average Price (US$/Dose) & (2021-2032) Figure 6. Global Bevacizumab Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg Image Figure 10. 400mg Image Figure 11. Global Bevacizumab Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 12. Global Bevacizumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Bevacizumab Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Bevacizumab Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Bevacizumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Bevacizumab Injection Sales Value Share by Type (2021-2032) Figure 17. Age-related macular degeneration (AMD) Image Figure 18. Ovarian Cancer Image Figure 19. Others Image Figure 20. Global Bevacizumab Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 21. Global Bevacizumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Bevacizumab Injection Sales Volume Share by Application (2021-2032) Figure 23. Global Bevacizumab Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Bevacizumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Bevacizumab Injection Sales Value Share by Application (2021-2032) Figure 26. Global Bevacizumab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 27. Global Bevacizumab Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Bevacizumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Bevacizumab Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Bevacizumab Injection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Bevacizumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Bevacizumab Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Bevacizumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Bevacizumab Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Bevacizumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Bevacizumab Injection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Bevacizumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Bevacizumab Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Bevacizumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Bevacizumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Bevacizumab Injection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Bevacizumab Injection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 400mg
Applications
  • Age-related macular degeneration (AMD)
  • Ovarian Cancer
  • Others
Companies covered
  • Biocon
  • Cadila Pharmaceuticals
  • Centus
  • Dr Reddy's
  • Genentech
  • Hetero Group
  • Samsung Bioepis
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bevacizumab Injection Sales Value (2021-2032)
  4. 1.2.2 Global Bevacizumab Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Bevacizumab Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Bevacizumab Injection Market Dynamics
  1. 2.1 Bevacizumab Injection Industry Trends
  2. 2.2 Bevacizumab Injection Industry Drivers
  3. 2.3 Bevacizumab Injection Industry Opportunities and Challenges
  4. 2.4 Bevacizumab Injection Industry Restraints
3 Bevacizumab Injection Market by Company
  1. 3.1 Global Bevacizumab Injection Company Revenue Ranking in 2025
  2. 3.2 Global Bevacizumab Injection Revenue by Company (2021-2026)
  3. 3.3 Global Bevacizumab Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Bevacizumab Injection Average Price by Company (2021-2026)
  5. 3.5 Global Bevacizumab Injection Company Ranking (2024-2026)
  6. 3.6 Global Bevacizumab Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Bevacizumab Injection Company Product Type and Application
  8. 3.8 Global Bevacizumab Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Bevacizumab Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Bevacizumab Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Bevacizumab Injection Market by Type
  1. 4.1 Bevacizumab Injection Type Introduction
  2. 4.1.1 100mg
  3. 4.1.2 400mg
  4. 4.2 Global Bevacizumab Injection Sales Volume by Type
  5. 4.2.1 Global Bevacizumab Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Bevacizumab Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Bevacizumab Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Bevacizumab Injection Sales Value by Type
  9. 4.3.1 Global Bevacizumab Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Bevacizumab Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Bevacizumab Injection Sales Value Share by Type (2021-2032)
5 Bevacizumab Injection Market by Application
  1. 5.1 Bevacizumab Injection Application Introduction
  2. 5.1.1 Age-related macular degeneration (AMD)
  3. 5.1.2 Ovarian Cancer
  4. 5.1.3 Others
  5. 5.2 Global Bevacizumab Injection Sales Volume by Application
  6. 5.2.1 Global Bevacizumab Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bevacizumab Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Bevacizumab Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Bevacizumab Injection Sales Value by Application
  10. 5.3.1 Global Bevacizumab Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Bevacizumab Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Bevacizumab Injection Sales Value Share by Application (2021-2032)
6 Bevacizumab Injection Regional Sales and Value Analysis
  1. 6.1 Global Bevacizumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bevacizumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Bevacizumab Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Bevacizumab Injection Sales by Region (2027-2032)
  5. 6.3 Global Bevacizumab Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Bevacizumab Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Bevacizumab Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Bevacizumab Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Bevacizumab Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Bevacizumab Injection Sales Value (2021-2032)
  12. 6.6.2 North America Bevacizumab Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Bevacizumab Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Bevacizumab Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Bevacizumab Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Bevacizumab Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Bevacizumab Injection Sales Value (2021-2032)
  21. 6.9.2 South America Bevacizumab Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Bevacizumab Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Bevacizumab Injection Sales Value Share by Country, 2025 VS 2032
7 Bevacizumab Injection Country-level Sales and Value Analysis
  1. 7.1 Global Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Bevacizumab Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Bevacizumab Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Bevacizumab Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Bevacizumab Injection Sales by Country (2027-2032)
  6. 7.4 Global Bevacizumab Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Bevacizumab Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Bevacizumab Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Bevacizumab Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Bevacizumab Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Bevacizumab Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocon
  2. 8.1.1 Biocon Company Information
  3. 8.1.2 Biocon Business Overview
  4. 8.1.3 Biocon Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biocon Bevacizumab Injection Product Portfolio
  6. 8.1.5 Biocon Recent Developments
  7. 8.2 Cadila Pharmaceuticals
  8. 8.2.1 Cadila Pharmaceuticals Company Information
  9. 8.2.2 Cadila Pharmaceuticals Business Overview
  10. 8.2.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
  12. 8.2.5 Cadila Pharmaceuticals Recent Developments
  13. 8.3 Centus
  14. 8.3.1 Centus Company Information
  15. 8.3.2 Centus Business Overview
  16. 8.3.3 Centus Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Centus Bevacizumab Injection Product Portfolio
  18. 8.3.5 Centus Recent Developments
  19. 8.4 Dr Reddy's
  20. 8.4.1 Dr Reddy's Company Information
  21. 8.4.2 Dr Reddy's Business Overview
  22. 8.4.3 Dr Reddy's Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dr Reddy's Bevacizumab Injection Product Portfolio
  24. 8.4.5 Dr Reddy's Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Genentech Bevacizumab Injection Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Hetero Group
  32. 8.6.1 Hetero Group Company Information
  33. 8.6.2 Hetero Group Business Overview
  34. 8.6.3 Hetero Group Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hetero Group Bevacizumab Injection Product Portfolio
  36. 8.6.5 Hetero Group Recent Developments
  37. 8.7 Samsung Bioepis
  38. 8.7.1 Samsung Bioepis Company Information
  39. 8.7.2 Samsung Bioepis Business Overview
  40. 8.7.3 Samsung Bioepis Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
  42. 8.7.5 Samsung Bioepis Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Bevacizumab Injection Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Bevacizumab Injection Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Bevacizumab Injection Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Eli Lilly
  62. 8.11.1 Eli Lilly Company Information
  63. 8.11.2 Eli Lilly Business Overview
  64. 8.11.3 Eli Lilly Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly Bevacizumab Injection Product Portfolio
  66. 8.11.5 Eli Lilly Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Roche Bevacizumab Injection Product Portfolio
  72. 8.12.5 Roche Recent Developments
  73. 8.13 Mylan
  74. 8.13.1 Mylan Company Information
  75. 8.13.2 Mylan Business Overview
  76. 8.13.3 Mylan Bevacizumab Injection Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Mylan Bevacizumab Injection Product Portfolio
  78. 8.13.5 Mylan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bevacizumab Injection Value Chain Analysis
  2. 9.1.1 Bevacizumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bevacizumab Injection Sales Mode & Process
  6. 9.2 Bevacizumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bevacizumab Injection Distributors
  9. 9.2.3 Bevacizumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst